Related Experiment Video
Updated: Feb 4, 2026

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
Published on: January 22, 2019
Reversing anti-factor Xa agents and the unmet needs in trauma patients
Beverley J Hunt1,2, Matthew D Neal3, Jakob Stensballe4,5
1Thrombosis and Haemostasis, King's College London, London, United Kingdom.
Abstract:
Andexanet alfa, a reversing agent for anticoagulants that inhibit factor Xa, has recently been licensed in the United States. We discuss the impact of this licensure on current practice and review in detail the problems of a neglected and growing clinical area: reversing the anticoagulation effect of factor Xa inhibitors in bleeding trauma patients. We identify areas of practice that need research so that care of bleeding trauma patients receiving direct factor Xa inhibitors can be improved.
More Related Videos
Related Concept Videos
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Transcription Factors
Reversible and Irreversible Processes
Diode: Reverse bias
Subviral Agents

